Johnson & Johnson next month plans a Phase III coronavirus-vaccine trial with up to 60,000 healthy people ages 18 and older.

Johnson & Johnson will buy Momenta for $6.5 billion in an all-cash deal. That's not disrupting the chart though, which has breakout potential for the stock.

J&J will buy Momenta Pharmaceuticals for roughly $6.5 billion in cash, paving the way for its Janssen unit to expand its efforts into autoimmune disease treatments.

Momenta's proposed inflammatory blood disease therapy, M254, could provide an alternative to the current, IV-based treatment, says an analyst.

This is the second generic Copaxone 40 mg/mL greenlighted by the U.S. Food and Drug Administration.

State attorneys general led by Connecticut's George Jepsen said Tuesday that were planning to include Mylan president Rajiv Malik and Emcure Pharmaceuticals Ltd. executive Satish Mehta in an expanded complaint in the federal generic drug antitrust lawsuit.

Analysts are most critical about Teva's plan to cut $5 billion in debt by the end of the year.

Teva said weak U.S. markets and the ongoing political turmoil in Venezuela weighed on the company's second quarter performance.

Generic drugmakers are likely to limit themselves to acquisitions of small- and mid-sized companies in the immediate future because of over-leveraging and turmoil in the executive ranks..

Regal Cinemas parent Cineworld is evaluating ways to generate liquidity and possibly restructure the balance sheet, a media report says..

If you’re walking out of a big-box grocery retailer feeling as if you’ve dug a lot deeper at the checkout, you’re not imagining things.

Deere's third quarter profits "reflected higher costs and production inefficiencies driven by the difficult supply-chain situation," said CEO John May.